Journal article icon

Journal article

New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

Abstract:
BACKGROUND: The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. METHODS: In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0-N1) were randomised. We investigated the impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus EBRT vs. EBRT. RESULTS: Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt . Non-breast cancer mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI 0.17-0.88) P = 0.0091. CONCLUSION: TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a good prognosis. TARGIT-IORT might have a beneficial abscopal effect. TRIAL REGISTRATION: ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009)
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1038/s41416-021-01440-8
Publication website:
https://discovery.dundee.ac.uk/files/58916484/s41416_021_01440_8.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0003-1760-1278
More by this author
Role:
Author
ORCID:
0000-0002-8033-6123
More by this author
Role:
Author
ORCID:
0000-0001-8837-5920
More by this author
Role:
Author
ORCID:
0000-0001-6037-0853
More by this author
Role:
Author
ORCID:
0000-0003-4717-0544


More from this funder
Funder identifier:
10.13039/501100002347
Grant:
FKZ 01ZP0508
More from this funder
Funder identifier:
10.13039/501100000664
Grant:
HTA 10/04/07
HTA 07/60/49
HTA 14/49/13
HTA 07/60/49
HTA 10/04/07
HTA 14/49/13
HTA 07/60/49
HTA 10/04/07
HTA 14/49/13
HTA 10/04/07
HTA 14/49/13
HTA 10/04/07
HTA 07/60/49
HTA 10/04/07
HTA 14/49/13
HTA 07/60/49
HTA 14/49/13
HTA 07/60/49
HTA 10/04/07
HTA 14/49/13


Publisher:
Springer Nature [academic journals on nature.com]
Journal:
British Journal of Cancer More from this journal
Volume:
125
Issue:
3
Pages:
380-389
Publication date:
2021-05-25
DOI:
EISSN:
1532-1827
ISSN:
0007-0920


Language:
English
Keywords:
Pubs id:
1179436
Local pid:
pubs:1179436
Source identifiers:
W3164978296
Deposit date:
2026-03-24
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP